The new distribution facility will support ambient and cold chain storage of investigational medicines and will be DEA approved for storage of Schedule II-V controlled substances. Also, its close proximity to the airport offers convenient international access. PCI currently distributes clinical/investigational medicines to investigator sites around the world and industry trends show continued growth of clinical studies in emerging markets such as South America, Asia, Russia, and Eastern Europe.
“We are very excited about the opportunity to build out our distribution capabilities in support of business growth,” said Bob Misher, senior vice president of Global Clinical Services at PCI. “The ability to package, store, globally distribute, and process returns of investigational medicines all in one state-of-the-art campus is a real benefit to our clients. This new facility helps us strategically position our business to further support industry trends we are witnessing; the first being international growth in the execution of our clients’ clinical studies, and the second being clients’ investigational medicines needing Cold Chain storage and shipment at 2-8°C, -20°C, and -80°C. We have been steadily expanding our capabilities in these areas as industry dynamics change. The location is built to be very accommodating as the industry and the needs of our clients evolve in years to come.”